AI Article Synopsis
- Cytokine storm syndrome (CSS) is a severe complication in COVID-19 patients, with treatment typically being tocilizumab, although the role of glucocorticoids (GC) remains debated.
- A study involving 92 COVID-19 patients with CSS assessed the outcomes of those treated with GC alone, GC plus tocilizumab, and tocilizumab alone, measuring various health markers and mortality rates.
- Results indicated that patients receiving GC showed lower event rates (like intubation and death) compared to those receiving only tocilizumab, suggesting that early GC use may improve survival and reduce the need for additional treatments.
Article Abstract
Introduction: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.
Patients: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.
Results: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.
Discussion: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351423 | PMC |
| http://dx.doi.org/10.1016/j.medcle.2020.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!